Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Pasireotide (Primary)
- Indications Thymoma
- Focus Proof of concept; Therapeutic Use
- 02 Mar 2016 Status changed from active, no longer recruiting to completed, according to European Clinical Trials Database record.
- 24 Nov 2014 Planned End Date changed from 1 Dec 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
- 24 Nov 2014 Planned primary completion date changed from 1 Dec 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.